- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.10. | BMS' hyped schizophrenia launch Cobenfy delivers so-so launch year as execs map plan for future | ||
| 30.10. | As vaccines industry struggles, Merck's adult pneumococcal shot Capvaxive off to strong start | ||
| 30.10. | Lilly's Zepbound, Mounjaro show out with $10B quarter despite CVS formulary hitch | ||
| 30.10. | Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera | ||
| 29.10. | Amid Trump admin's drug pricing push, FDA aims to give biosimilars a boost | ||
| 29.10. | Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind' | ||
| 29.10. | Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival miss | ||
| 29.10. | Akebia scraps plan for Vafseo trial after discussions with FDA | ||
| 29.10. | Emma Walmsley upholds £40B sales target in her final GSK CEO report | ||
| 29.10. | Lilly earmarks $1.2B for upgrades to Puerto Rico plant to boost oral drug production capacity | ||
| 28.10. | Merck eyes life after Keytruda LOE with Welireg kidney cancer wins | ||
| 28.10. | Kenvue readies defenses as Texas AG sues over alleged Tylenol-autism link | ||
| 28.10. | Regeneron reports another manufacturing-related rejection for Eylea HD, but says help is on the way | ||
| 28.10. | BioMarin resigned to ending journey with hemophilia A gene therapy Roctavian, seeks divestiture amid sales struggle | ||
| 28.10. | Newer drugs came to Novartis' aid as 2 top-selling blockbusters stalled in Q3 | ||
| 28.10. | CSL delays flu vaccine unit spinoff as US immunization rates plummet | ||
| 28.10. | Birds, lizards and cats, oh my: FDA blasts generic drug maker Hetero in scathing Form 483 | ||
| 28.10. | After lupus nephritis nod, Roche keeps Gazyva momentum rolling with phase 3 win in another kidney condition | ||
| 27.10. | Cigna's Express Scripts set to shift away from PBM rebates | ||
| 27.10. | Merck nabs updated FDA label for soon-to-be-blockbuster Winrevair | ||
| 27.10. | Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study | ||
| 27.10. | UK watchdog slams AstraZeneca, Organon for marketing breaches | ||
| 27.10. | Organon CEO exits, company goes on hunt for successor as internal probe turns up 'improper' Nexplanon sales tactics | ||
| 24.10. | With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds | ||
| 24.10. | For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .